During this webinar series, Dr. Rouzier has discussed how to educate your patients with research that informs the patient on what to expect from the therapy and not to focus on the laboratory numbers. Numbers should be utilized as a guide to therapy but does not correlate with symptom improvement. In this webinar, Dr. Rouzier will provide additional literature that demonstrates what levels patients experience improvement in symptoms, but with no clear recommendation as to when the lab tests should be performed. This month’s literature review will focus on improvement in disease and illness with testosterone replacement therapy in women.
Upon completion of this workshop, the healthcare professional will be able to:
- Appreciate that most studies. Demonstrate that high testosterone and estradiol levels are associated with an increased risk of breast cancer. However, ADNPC.
- Review and be able to explain that most studies demonstrate the opposite when testosterone is administered for menopausal HRT. Baseline levels suggesting harm should not be extrapolated to what happens when testosterone is administered.
- Evaluate studies demonstrating that testosterone administration is beneficial in protecting against breast cancer in contrast to baseline-observation studies suggesting that high levels are “associated” with harm.
- Critique a recent study from Menopause 2011 demonstrating significant improvements were observed only at the highest dose of testosterone enanthate, which was associated with supraphysiologic on-treatment testosterone concentrations.
- Review recent medical studies demonstrating that outcome studies result in a reduction in the incidence of breast cancer with the use of testosterone.
- Review similar literature proving a reduction in breast cancer recurrence in breast cancer survivors.
- Discuss the importance of stimulating the AR by DHT for breast protection.
- Review and be able to explain that most studies demonstrate the opposite when testosterone is administered for menopausal HRT.